Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab

(Impact Journals LLC) This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news